Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laparoscopic ileocolic resection versus infliximab for recurrent terminal ileal Crohn's disease
NL-OMON31330Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab in Crohn's disease (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Disease-specific quality of life and Costs per QALY. Planned start Dec 2007; status: not yet recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON31330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31330.